Chronic Myelogenous Leukemia (CML) Clinical Trials


Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Conditions:   Activating RAS Mutation;   Juvenile Myelomonocytic Leukemia;   Monosomy 7;   Neurofibromatosis Type 1;   NF1 Gene Mutation;   PTPN11 Gene Mutation;   Splenomegaly
Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Trametinib
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting - verified June 2017

Learn More

Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT

Conditions:   Non-Hodgkin's Lymphoma;   Acute Leukemia in Remission;   Chronic Myeloid Leukemia;   Primary Myelofibrosis;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndromes;   Hodgkin Lymphoma;   Multiple Myeloma
Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Drug: Cyclophosphamide;   Radiation: Total body irradiation (TBI);   Procedure: Peripheral Blood Hematopoietic Cell Transplantation (HCT);   Drug: Sirolimus (SIR);   Drug: Mycophenolate mofetil (MMF);   Drug: Granulocyte-colony stimulating factor (G-CSF)
Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
Recruiting - verified July 2017

Learn More

Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation

Condition:   Leukemia
Interventions:   Drug: Rituximab;   Drug: Melphalan;   Drug: Fludarabine;   Radiation: Total body irradiation (TBI);   Procedure: Stem Cell Infusion;   Drug: Cyclophosphamide;   Drug: G-CSF
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified June 2017

Learn More

Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia

Condition:   Leukemia, Myelomonocytic, Chronic
Intervention:   Drug: Tipifarnib
Sponsor:   Kura Oncology, Inc.
Recruiting - verified July 2017

Learn More

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia/Lymphoma;   Burkitt's Lymphoma;   Natural Killer Cell Malignancies;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Relapsed Chronic Lymphocytic Leukemia;   Relapsed Small Lymphocytic Lymphoma;   Marginal Zone B-cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-cell Lymphoma;   Prolymphocytic Leukemia;   Bone Marrow Failure Syndromes;   Myeloproliferative Neoplasms/Myelofibrosis;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Leukemia or MDS in Aplasia;   Relapsed T-Cell Lymphoma;   Relapsed Multiple Myeloma;   Plasma Cell Leukemia
Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: MMF;   Drug: Sirolimus;   Radiation: TBI;   Biological: Umbilical cord blood cell infusion;   Biological: ATG
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified June 2017

Learn More

Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients

Conditions:   Hematological Malignancies;   Acute Lymphoblastic Leukemia (ALL);   Acute Myelogenous Leukemia (AML);   Chronic Myelogenous Leukemia (CML);   Myelodysplastic Syndrome (MDS)
Interventions:   Drug: NiCord®;   Other: Cord Blood Unit
Sponsor:   Gamida Cell ltd
Recruiting - verified June 2017

Learn More

A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant

Conditions:   Acute Myeloid Leukemia (AML);   Chronic Myelogenous Leukemia (CML);   Myelodysplastic Syndrome (MDS);   Chronic Myelomonocytic Leukemia (CMML)
Interventions:   Drug: CD24Fc;   Drug: Methotrexate;   Drug: Tacrolimus;   Other: Placebo
Sponsors:   OncoImmune, Inc.;   Ohio State University;   University of Michigan Cancer Center
Recruiting - verified June 2017

Learn More

WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Conditions:   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Myelodysplastic/Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: Cytarabine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: WEE1 Inhibitor AZD1775
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified September 2016

Learn More

Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia

Conditions:   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: Belinostat;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: WEE1 Inhibitor AZD1775
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified May 2017

Learn More

A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In 1st Line MDS, AML and CMML Patients

Condition:   Myelodysplastic Syndrome
Interventions:   Drug: PF-04449913 (Glasdegib);   Drug: Azacitidine;   Drug: PF-04449913 (Glasdegib) Placebo
Sponsor:   Pfizer
Recruiting - verified June 2017

Learn More

Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome (PC) Positive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML)

Condition:   Leukemia
Interventions:   Drug: Bosutinib;   Drug: Inotuzumab Ozogamicin;   Behavioral: Phone Call
Sponsors:   M.D. Anderson Cancer Center;   Pfizer
Recruiting - verified June 2017

Learn More

Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections

Conditions:   Chronic Lymphocytic Leukemia;   CML (Chronic Myelogenous Leukemia);   MDS (Myelodysplastic Syndrome);   Acute Lymphoblastic Leukemia;   AML (Acute Myelogenous Leukemia)
Interventions:   Biological: MVST;   Biological: MVSTr
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 23, 2017

Learn More

Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation

Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myelogenous Leukemia (AML);   Chronic Lymphocytic Leukemia (CLL);   Chronic Myelogenous Leukemia (CML);   MDS
Intervention:   Device: CliniMACS CD34 selection system
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2, 2017

Learn More

Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

Condition:   Previously Treated PH + CML
Intervention:   Drug: Bosutinib
Sponsors:   Pfizer;   Developmental Therapeutics Consortium
Recruiting - verified June 2017

Learn More

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Lymphoblastic Lymphoma;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Thiotepa;   Radiation: Total-Body Irradiation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2017

Learn More

1-15 of 26
Results per page

Join the community!


You must be a member of healtheo360 in order to view this group

Register with Email Address

Already a member? Click here to login

healtheo360 believes strongly in user privacy.